|
| |
|
 |
| |
ImClone Systems is dedicated to developing and commercializing novel therapeutic products in the field of
oncology. Our efforts have resulted in a commercially available novel therapy, ERBITUX® (cetuximab), as well
as a broad spectrum of innovative product candidates with potential application in multiple tumor types. As
a member of the oncology community, we are committed to providing treatments to meet the unmet needs of cancer
patients. To fulfill this commitment, ImClone Systems fosters integration of the principles of teamwork and
scientific integrity into all facets of the Company's activities. We believe that these values will benefit
patients, physicians, and our employees while creating value for our shareholders.
Operations
ImClone Systems operates in two locations - its corporate and scientific headquarters at 180 Varick Street in
New York City, which houses the Company's research and executive offices, and its campus in Branchburg, New
Jersey. The Branchburg facility is home to the manufacturing, product development, finance, clinical, regulatory
and quality assurance and commercial operations departments.
History
The Company was founded in 1984 and in 1986, opened its laboratories at 180 Varick Street in New York City. In
its early years, the Company focused on immunology-based diagnostics and infectious disease vaccines. This focus
resulted in two FDA approved diagnostics and several vaccine research programs, all of which have been licensed to
pharmaceutical companies. During the early 1990s, the Company's focus shifted from diagnostics and infectious
disease to the development of a pipeline of innovative, biologic compounds in the area of oncology. From this
pipeline, the Company markets ERBITUX®, which received its first FDA indication approval in 2004, and it has a
number of investigational monoclonal antibodies in various stages of clinical development.
|
|
